title: Synergistic effect of combining theophylline and drugs that potentially elevate serum creatine kinase.
abstract: An increase in the serum creatine kinase (CK) level is one of the side effects of theophylline; on rare occasions, the increase may be followed by rhabdomyolysis. Theophylline is often administered with drugs that potentially elevate the serum CK level (CK-elevating drugs) such as beta-agonists and steroids. However, the effects of the combined treatment of theophylline and CK-elevating drugs have not been reported. We, therefore, retrospectively investigated the effects of combined treatment on the serum CK level, in 391 asthmatic outpatients. In this study, the number and type of the CK-elevating drugs administered, and the serum levels of CK and theophylline, were investigated. The patients were divided into four groups: the theophylline-treated and CK-elevating drug-treated group, the theophylline-treated and non-CK-elevating drug-treated group, the non-theophylline-treated and CK-elevating drug-treated group, and the non-theophylline-treated and non-CK-elevating drug-treated group. The theophylline-treated and CK-elevating drug-treated group showed about 100% higher serum CK levels (225 IU/L) than any other group (102-124 IU/L), and no increase in the serum theophylline level. This result indicates that there is a synergistic effect of theophylline and CK-elevating drugs on the serum CK level. The combined treatment of theophylline and CK-elevating drugs induces a synergistic increase in the serum CK level, indicating not pharmacokinetic but pharmacodynamic interactions with these drugs.
authors.affiliation: Department of Clinical Pharmacology, University of Tokushima Faculty of Pharmaceutical Sciences, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Iwano
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Izumida
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: Y
authors.initials: Y
authors.lastname: Takiguchi
authors.forename: K
authors.initials: K
authors.lastname: Minakuchi
authors.forename: S
authors.initials: S
authors.lastname: Sone
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001249:Asthma / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013256:Steroids / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D013806:Theophylline / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000960:Hypolipidemic Agents; D013256:Steroids; D013806:Theophylline; D003402:Creatine Kinase